Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
Tom Abate’s reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner. –Thom Calandra, editor in chief, CBS MarketWatch
In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies for - tracking the effect of breaking news and the NASDAQ - anticipating drug trial announcements and FDA approvals - assessing the potential market, patent rights, and distribution deals for a drug He looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century’s most promising industries.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
Tom Abate’s reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner. –Thom Calandra, editor in chief, CBS MarketWatch
In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies for - tracking the effect of breaking news and the NASDAQ - anticipating drug trial announcements and FDA approvals - assessing the potential market, patent rights, and distribution deals for a drug He looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century’s most promising industries.